Thread- reinforced encapsulation devices (THRED) for therapeutic stem cell delivery.

Area of Science:

• Regenerative Medicine
• Biomaterials Science
• Gastroenterology

Background:

• Mesenchymal stem cells (MSCs) show therapeutic potential but face challenges like limited longevity and tumorigenicity.
• Immune rejection and poor survival hinder widespread clinical application of MSCs.
• Developing effective delivery systems is crucial for harnessing MSC therapeutic benefits, especially for conditions like intestinal ischemic diseases.

Purpose of the Study:

• To evaluate an encapsulation and delivery method for mesenchymal stem cells (MSCs).
• To assess the therapeutic potential of encapsulated MSCs for treating intestinal ischemic diseases.

Main Methods:

• Human vertebra bone adherent MSCs (vBA-MSCs) were encapsulated in an alginate-derived Thread Reinforced Encapsulation Device (THRED).
• Encapsulated vBA-MSCs were assessed for viability, surface marker expression, and cytokine production.
• The therapeutic efficacy of encapsulated MSCs was tested in a mouse model of intestinal ischemia-reperfusion injury.

Main Results:

• Successful encapsulation of vBA-MSCs within the THRED device was achieved.
• Encapsulated MSCs maintained viability, functionality, and characteristic cell surface markers.
• Treatment with encapsulated MSCs significantly improved intestinal injury scores in the mouse model.

Conclusions:

• The THRED device represents a viable strategy for delivering MSCs in therapeutic applications.
• Further research is required to optimize cell dosage and delivery duration for maximal therapeutic benefit.